Inside Penn

In brief, what’s happening at Penn—whether it’s across campus or around the world.

Filter Stories

Displaying 11 - 20 of 951
  • Model simulations point to key concerns for reopening the economy

    As two-thirds of the 50 states began relaxing their anti-COVID-19 restrictions, the sixth in a series of seminars, “Experts at Home,” convened by Penn LDI, brought together scientists who have created different simulator models to predict the economic and health changes various levels of policy relaxations may bring.

    FULL STORY AT Leonard Davis Institute

  • Leadership gift to accelerate neuroscience at Wharton and create actionable insights in brain science and business

    The anonymous $10 million will amplify opportunities and outcomes of the Wharton Neuroscience Initiative (WiN). This commitment will propel faculty research and teaching, student learning, and corporate engagement through WiN.

    FULL STORY AT Wharton

  • The front-line researchers: The next generation of scientists steps up to fight the pandemic

    Perelman School of Medicine scientists and clinicians have begun an unprecedented number of studies and clinical trials investigating a single virus, SARS-CoV-2, and COVID-19. But it’s not just the seasoned, established investigators—graduate students, postdoctoral researchers, and laboratory technicians have also dedicated their energy and efforts to fight this virus.

    FULL STORY AT Penn Medicine News

  • New ideas in urban research 2020

    The May issue of Urban Link highlights graduating Ph.D. students’ research on urban-related topics, including applied economics, city and regional planning, criminology, and nursing. 

    FULL STORY AT Penn IUR

  • Keys to avoiding delirium: good sleep, proper medication, effective caregivers

    Penn Memory Center Co-Director Dr. Jason Karlawish and Deborah Kan define what delirium is, the reasoning behind why those with dementia are more susceptible to developing delirium, and what caregivers should do during this time to prepare themselves and the ones they care for. 

    FULL STORY AT Penn Memory Center

  • Wharton Global Youth Program annual Knowledge@Wharton High School Investment Competition winners announced

    This year’s Global Finale, held via live video conference, was the culmination of an engaging financial competition for high school students and educators around the world that began more than six months ago, with student teams managing portfolios of $100,000 in virtual cash and building unique team investment strategies.

    FULL STORY AT Wharton

  • Toni Walker visits South Africa to study Black womxn and queer artists

    Graduating Communication major Toni Walker spent 12 days in South Africa conducting research as part of her undergraduate fellowship with the Annenberg School’s Center for Advanced Research in Global Communication. 

    FULL STORY AT Annenberg School for Communication

  • New ‘Thriving in the Law’ course equips young lawyers with tools to increase fulfillment in the profession

    The new course, designed and taught by Law School Associate Dean John F. Hollway explores the tools and strategies necessary to equip lawyers to handle the social and emotional aspects of lawyering.

    FULL STORY AT Penn Law

  • The optimist’s Venice Biennale preview

    The theme of the 17th International Architecture Exhibition—La Biennale di Venezia, “How will we live together?” has assumed a new significance as the coronavirus pandemic has swept across the globe. As health concerns led to shutdowns in Italy, the Biennale’s opening was postponed until August 29, but the Weitzman School stands to be well represented if the landmark event can take place.

    FULL STORY AT Weitzman School of Design

  • Updated data show promise of targeted therapy in Castleman disease

    David C. Fajgenbaum, a Penn Medicine researcher and Castleman disease patient, and his team demonstrated that there is increased activation of a specific pathway called PI3K/Akt/mTOR. The findings suggest that Castleman patients who do not respond to the only drug currently approved by the U.S. Food and Drug Administration for the treatment of the disease may have another option that targets this specific pathway. 

    FULL STORY AT Penn Medicine News